Based on our in vitro results, in particular the ability of non-toxic carborane-based ABCG2 inhibitors to affect ABC transporter-associated doxorubicin and cisplatin efflux, thus sensitizing the examined cancer cells for the applied therapeutics, future in vivo studies are of interest. This evidence concerns the gene ABCG2 and cancer.